Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.
2019 novel coronavirus infection
2019-nCoV infection
arbidol
coronavirus
novel coronavirus
umifenovir
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
10
07
2021
received:
13
03
2021
accepted:
16
07
2021
pubmed:
5
8
2021
medline:
18
11
2021
entrez:
4
8
2021
Statut:
ppublish
Résumé
To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID-19 treatment. A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle-Ottawa scale were used to assess the quality of included studies. Meta-analysis was performed using RevMan 5.3. Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non-antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR-PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78-1.14) and Day 14 (RR: 1.10; 95% CI: 0.96-1.25), and PCR negative conversion time (PCR-NCT; mean difference [MD]: 0.74; 95% CI: -0.87 to 2.34), nor secondary outcomes (p > .05). However, arbidol was associated with higher adverse events (RR: 2.24; 95% CI: 1.06-4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes (p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR-PCR on Day 7 and PCR-NCT (p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes (p > .05). No remarkable therapeutic effect was observed between arbidol and other agents (p > .05). The present meta-analysis showed no significant benefit of using arbidol compared with non-antiviral treatment or other therapeutic agents against COVID-19 disease. High-quality studies are needed to establish the efficacy and safety of arbidol for COVID-19.
Identifiants
pubmed: 34347937
doi: 10.1002/iid3.502
pmc: PMC8426686
doi:
Substances chimiques
Antiviral Agents
0
Indoles
0
umifenovir
93M09WW4RU
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1197-1208Informations de copyright
© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Arch Virol. 2009;154(4):601-7
pubmed: 19291363
Front Public Health. 2020 May 29;8:249
pubmed: 32574310
Med (N Y). 2020 Dec 18;1(1):105-113.e4
pubmed: 32838353
Front Pharmacol. 2020 Sep 18;11:560209
pubmed: 33071781
Clin Microbiol Infect. 2020 Jul;26(7):917-921
pubmed: 32344167
Int J Clin Pharmacol Ther. 2021 May;59(5):378-385
pubmed: 33624583
J Nepal Health Res Counc. 2020 Apr 19;18(1):1-9
pubmed: 32335585
Pharmacol Res. 2020 Jul;157:104854
pubmed: 32360585
Expert Rev Respir Med. 2021 Feb;15(2):257-265
pubmed: 32941741
J Med Virol. 2021 Jan;93(1):481-490
pubmed: 32617989
Antiviral Res. 2011 Jun;90(3):99-107
pubmed: 21440006
Antiviral Res. 2014 Jul;107:84-94
pubmed: 24769245
Int J Antimicrob Agents. 2020 Aug;56(2):105998
pubmed: 32360231
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
J Infect. 2020 Jul;81(1):e21-e23
pubmed: 32283143
Sci Total Environ. 2020 Jul 10;725:138277
pubmed: 32278175
Ann Palliat Med. 2021 Mar;10(3):3307-3312
pubmed: 33849115
Biochemistry. 2007 May 22;46(20):6050-9
pubmed: 17455911
Zhonghua Nei Ke Za Zhi. 2020 Aug 1;59(8):605-609
pubmed: 32388937
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
J Infect. 2020 Jul;81(1):e1-e5
pubmed: 32171872
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
J Med Virol. 2012 Jan;84(1):170-81
pubmed: 22028179
Acta Pharmacol Sin. 2013 Aug;34(8):1075-83
pubmed: 23770981
Ter Arkh. 2019 Mar 30;91(3):56-63
pubmed: 31094461
Microbes Infect. 2020 May - Jun;22(4-5):200-205
pubmed: 32445881
Virol J. 2020 Oct 23;17(1):162
pubmed: 33097047
BMC Infect Dis. 2020 Dec 14;20(1):954
pubmed: 33317461
Sci Rep. 2018 Jun 12;8(1):8989
pubmed: 29895962
Immun Inflamm Dis. 2021 Dec;9(4):1197-1208
pubmed: 34347937
Ann Palliat Med. 2021 Mar;10(3):2429-2438
pubmed: 33440980
Cell Discov. 2020 May 2;6:28
pubmed: 32373347
J Med Virol. 2019 Apr;91(4):588-597
pubmed: 30431664
Arch Virol. 2007;152(8):1447-55
pubmed: 17497238
Curr Med Sci. 2021 Sep 13;:
pubmed: 34515914
Eur J Phys Rehabil Med. 2019 Jun;55(3):353-363
pubmed: 30961346
J Med Virol. 2020 Nov;92(11):2702-2708
pubmed: 32510169
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30224531
Aging (Albany NY). 2021 Apr 3;13(7):9253-9264
pubmed: 33811756
J Virol. 2016 Jan 06;90(6):3086-92
pubmed: 26739045
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Medicine (Baltimore). 2021 Jan 29;100(4):e24475
pubmed: 33530261